Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious ...

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock ...

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one ...

Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly ...

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A ...

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI ...

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in ...

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically ...

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the ...

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.